Overview
Respiratory Regulatory Landscape
The regulatory environment for respiratory therapies involves specialized requirements from FDA Division of Pulmonary, Allergy, and Rheumatology Products, EMA CHMP Respiratory Working Party, PMDA Respiratory Review. This guide maps each requirement to ArcaScience's platform capabilities, demonstrating how AI-driven benefit-risk analysis aligns with and accelerates regulatory compliance.
Regulatory Requirements
Key Requirements by Agency
FDA Requirements
- ✓ Inhaled drug product safety requirements
- ✓ Asthma clinical trial endpoint guidance
- ✓ COPD exacerbation study design requirements
- ✓ Biologic safety monitoring for respiratory therapies
- ✓ Cystic fibrosis drug development guidance
EMA Requirements
- ✓ Guideline on clinical investigation of asthma
- ✓ COPD clinical development guidance
- ✓ Inhaler device safety requirements
- ✓ Respiratory biologic PSUR expectations
PMDA Requirements
- ✓ Japan-specific respiratory drug monitoring
- ✓ Inhaled product quality and safety requirements
- ✓ Post-marketing respiratory surveillance
ArcaScience Alignment
How ArcaScience Maps to Respiratory Requirements
Data Coverage
Respiratory-specific data from 47+ global sources, pre-harmonized and validated for regulatory submissions.
AI Models
Respiratory-trained AI models for adverse event classification, signal detection, and benefit quantification with regulatory validation.
Regulatory Outputs
Pre-formatted outputs aligned with FDA Division of Pulmonary, Allergy, and Rheumatology Products and EMA CHMP Respiratory Working Party submission requirements.
Download
Get the Full Respiratory Regulatory Landscape
Complete the form below to receive the document via email.
Related Resources